BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel. Show more

Location: 22 Einstein Street, Ness Ziona, 7414003, Israel | Website: https://www.biomx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

15.52M

52 Wk Range

$0.34 - $1.16

Previous Close

$0.58

Open

$0.65

Volume

350,979

Day Range

$0.58 - $0.65

Enterprise Value

27.78M

Cash

14.05M

Avg Qtr Burn

-7.302M

Insider Ownership

18.81%

Institutional Own.

44.48%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.